The European Medicines Agency said on Wednesday Wyeth had withdrawn its marketing authorisation application for desvenlafaxine, its drug designed to calm hot flushes in menopausal women.
The agency said Wyeth had pulled the application in order to conduct additional clinical studies to address questions by the Committee for Medicinal Products for Human Use, regarding the benefit-risk profile of the drug.
Reuters
No comments:
Post a Comment